Working with “living therapies” during COVID-19 has changed access, resource planning and management in CGT trials.
This ICON sponsored webinar program explores the bioethics of clinical trials at Preclinical and Phase 1 stages. An in-depth look at the unique nuances of cell and gene therapy (CGT) trials and how to keep them on track during COVID-19 will follow. The expert panel will conclude with a discussion on strategies for patient advocacy within this changed environment.
Register for the upcoming webinar to learn:
- What is the ethical protocol of approaching patients for early-stage clinical trials?
- What are the key differences between CGT clinical trials and traditional models?
- How has COVID-19 changed accessibility, resource planning and management of CGT trials?
- How has patient advocacy and support changed in the face of a global pandemic?
On-demand webinar archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.Access webinar archive
Global Business Lead, Cell and Gene Therapy, ICON
Steven Devine, MD, PhD
Chief Medical Officer, National Marrow Donor Program (NMDP)®/ Be The Match®
Patient Advocate and Founder, Raremark
Mark Yarborough, PhD
Dean’s Professor of Bioethics, University of California Davis
This webinar is sponsored by ICON in collaboration with the ISCT Market Access & Patient Advocacy (MAPA) Commercialization Subcommittee.